A trial for COYA 302, a potential treatment for amyotrophic lateral sclerosis (ALS), is expanding to Canada after receiving regulatory approval. The trial aims to test the effectiveness of COYA 302 in slowing ALS progression. Other companies, including Coya and BrainStorm, are also advancing their own ALS treatments, with some reporting promising results and others seeking regulatory clearance to begin clinical trials.